Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.

At each time point analysed, there was a consistent and highly significant reduced risk of moderate or severe exacerbation in the ITT population treated with salmeterol compared with usual therapy (28% during months 1–3, 24% during months 1–6 and 22% during months 1–12, p < 0.0001) Results were similar with the PR population (20–25% reduction in risk compared with usual therapy, p = 0.0002).

also in 132,142 other papers